补益宗气法治疗慢性阻塞性肺疾病稳定期疗效及对血清COX-2、MMP-9水平的影响
|
摘要
目的:探讨补益宗气法治疗慢性阻塞性肺疾病(COPD)稳定期的疗效及对血清环氧化酶-2(COX-2)、基质金属蛋白酶-9(MMP-9)水平的影响。方法:选取2014年6月—2017年3月医院收治的COPD稳定期患者122例,根据随机数字法分为对照组和观察组。对照组患者吸入可必特治疗,观察组在对照组治疗基础上联合补益宗气法治疗,分析两组患者治疗效果。结果:两组患者治疗后咳嗽、咳痰、气促、喘息评分均较治疗前下降,PEF、FEV1%及FVC水平均较治疗前上升,COX-2、PGE_2、MMP-9及TGF-β1水平均较治疗前下降(P <0. 05)。观察组患者治疗后临床症状评分、肺功能指标、COX-2、PGE2、MMP-9及TGF-β1水平均优于对照组(P <0. 05)。观察组患者治疗期间复发率低于对照组(P <0. 05)。结论:补益宗气法治疗COPD稳定期疗效确切,可改善临床症状和肺功能,降低血清COX-2、PGE2、MMP-9水平。
Objective:To investigate the effect of tonifying Qi and promoting Qi therapy on stable phase of chronic obstructive pulmonary disease( COPD) and its influence on serum cyclooxygenase-2( COX-2) and matrix metalloproteinase-9( MMP-9) levels. Methods:A total of 122 stable COPD patients from June 2014 to March 2017 in our hospital were randomly divided into control group and observation group. The control group inhaled combivent in the treatment and the observation group combined tonifying Qi and promoting Qi treatment. We analyzed the therapeutic effect of two groups. Results:Two groups' cough,expectoration,shortness of breath and wheezing scores after treatment were lower than those before treatment. PEF,FEV1% and FVC levels increased. Compared with those before treatment,COX-2,PGE_2,MMP-9 and TGF-β1 levels were lower than those before treatment( P < 0. 05). After treatment,clinical symptoms were observed,lung function indexes COX-2,PGE2,MMP-9 and TGF-beta 1 were better than those of the control group( P < 0. 05). Patients' recurrence rate in the observation group during the treatment was lower than that of the control group( P < 0. 05). Conclusion:The effect of tonifying Qi and Qi therapy on COPD stable phase is exact,which can improve the clinical symptoms and pulmonary function,and reduce the serum levels of COX-2,PGE2 and MMP-9.
Objective:To investigate the effect of tonifying Qi and promoting Qi therapy on stable phase of chronic obstructive pulmonary disease( COPD) and its influence on serum cyclooxygenase-2( COX-2) and matrix metalloproteinase-9( MMP-9) levels. Methods:A total of 122 stable COPD patients from June 2014 to March 2017 in our hospital were randomly divided into control group and observation group. The control group inhaled combivent in the treatment and the observation group combined tonifying Qi and promoting Qi treatment. We analyzed the therapeutic effect of two groups. Results:Two groups' cough,expectoration,shortness of breath and wheezing scores after treatment were lower than those before treatment. PEF,FEV1% and FVC levels increased. Compared with those before treatment,COX-2,PGE_2,MMP-9 and TGF-β1 levels were lower than those before treatment( P < 0. 05). After treatment,clinical symptoms were observed,lung function indexes COX-2,PGE2,MMP-9 and TGF-beta 1 were better than those of the control group( P < 0. 05). Patients' recurrence rate in the observation group during the treatment was lower than that of the control group( P < 0. 05). Conclusion:The effect of tonifying Qi and Qi therapy on COPD stable phase is exact,which can improve the clinical symptoms and pulmonary function,and reduce the serum levels of COX-2,PGE2 and MMP-9.
引文
[1]Detorres JP,Wilson DO,Sanchezsalcedo P,et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.[J]. American Journal of Respiratory&Critical Care Medicine,2015,191(3):285.
[2]万丽玲,兰智慧,张元兵,等.补益宗气对慢阻肺缓解期生活质量及肺功能的影响[J].辽宁中医杂志,2015,17(3):537-538.
[3]王明航,李建生.中医药治疗慢性阻塞性肺疾病临床疗效评价研究现状[J].中医杂志,2017,58(3):256-259.
[4]陈诗琪,杨欣宇,唐潇旖,等.喘可治注射液治疗慢性阻塞性肺疾病急性加重期的系统评价[J].中国中药杂志,2017,42(14):2789-2795.
[5]彭楠,路遥,赵晶,等.慢性阻塞性肺疾病肺气虚证肺容积成像定量分析与症状积分分级的研究[J].北京中医药大学学报,2016,39(5):424-428.
[6]Martineau AR,James WY,Hooper RL,et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease(Vi Di CO):a multicentre,double-blind,randomised controlled trial[J]. Lancet Respiratory Medicine,2015,3(2):120.
[7]姚欣,曹林峰,杨进,等.疏风解毒胶囊对慢性阻塞性肺疾病急性加重期的疗效评价[J].中华中医药杂志,2017,17(1):347-350.
[8]杜晓秋,周军,张秋娣.不同评价指标在慢性阻塞性肺疾病患者综合评估中的应用[J].中国全科医学,2016,11(5):511-516.
[9]王靓雅,刘冰,祖权,等.补肺健脾益肾方治疗稳定期慢性阻塞性肺疾病营养状况和对免疫功能的影响[J].中国实验方剂学杂志,2017,27(22):182-187.
[10]洪敏俐,杨朝阳,柯庚申,等.愈肺宁方对慢性阻塞性肺疾病稳定期患者中医证素的影响[J].中华中医药杂志,2015,9(5):1666-1669.
[11]潘宜,黄晓颖.布地奈德联合沙丁胺醇和异丙托溴铵治疗慢性阻塞性肺疾病急性发作期的临床研究[J].中国临床药理学杂志,2016,32(15):1347-1349.
[12]陈四清,谢文英,尚立芝,等.二陈汤加味对慢性阻塞性肺疾病急性加重期老年患者免疫功能及CCL18,CC16,IL-8和s ICAM-1的影响[J].中国实验方剂学杂志,2017,27(10):171-177.
[13]兰智慧,钟凌云,陈章生,等.补益宗气法对慢性阻塞性肺疾病大鼠气道重塑的影响[J].中华中医药学刊,2015,10(11):2659-2661.
[14]李建生,张海龙,王海峰,等.慢性阻塞性肺疾病证候演变特点临床调查[J].中医杂志,2017,58(9):772-776.
[15]郭贵州,宋文龙,甘桃梅,等.基于MMP-9/TIMP-1失衡研究补益宗气方干预慢性阻塞性肺疾病大鼠气道重塑的机制[J].中华中医药杂志,2016,16(11):4678-4680.
[16]王丽华,张元兵,兰智慧,等.国医大师洪广祥教授治疗慢性阻塞性肺疾病经验[J].中华中医药杂志,2016,10(7):2590-2592.
[17]郁东伟,束永前.中医综合疗法治疗慢性阻塞性肺疾病(COPD)稳定期营养状况及肺功能的改善评价[J].中华中医药学刊,2015,6(11):2608-2610.
[18]娄明远.中西医结合治疗不同严重度稳定期慢性阻塞性肺疾病的影响[J].中华中医药学刊,2017,35(9):2453-2455.
[19]张鹏飞,梁炜,谭玉萍,等.银杏叶提取物对慢性阻塞性肺疾病大鼠肺组织MMP-1及MMP-9表达的影响[J].辽宁中医杂志,2017,31(4):849-851.
[20]尤辉,王梅芳,刘玉全,等.乌司他丁对COPD合并呼吸衰竭患者血清COX-2,PGE2及PLA2的影响[J].现代生物医学进展,2015,15(35):6889-6891.
[21]何主强,殷莉,黄姗姗.环氧化酶-2及细胞因子在创伤后应激障碍患者中的表达变化及意义[J].实用医学杂志,2015,16(19):3166-3168.
[22]赵年昆,李岩.苏黄止咳胶囊治疗慢性阻塞性肺疾病急性发作期的临床疗效及长期随访观察[J].辽宁中医杂志,2017,19(6):1235-1238.
[2]万丽玲,兰智慧,张元兵,等.补益宗气对慢阻肺缓解期生活质量及肺功能的影响[J].辽宁中医杂志,2015,17(3):537-538.
[3]王明航,李建生.中医药治疗慢性阻塞性肺疾病临床疗效评价研究现状[J].中医杂志,2017,58(3):256-259.
[4]陈诗琪,杨欣宇,唐潇旖,等.喘可治注射液治疗慢性阻塞性肺疾病急性加重期的系统评价[J].中国中药杂志,2017,42(14):2789-2795.
[5]彭楠,路遥,赵晶,等.慢性阻塞性肺疾病肺气虚证肺容积成像定量分析与症状积分分级的研究[J].北京中医药大学学报,2016,39(5):424-428.
[6]Martineau AR,James WY,Hooper RL,et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease(Vi Di CO):a multicentre,double-blind,randomised controlled trial[J]. Lancet Respiratory Medicine,2015,3(2):120.
[7]姚欣,曹林峰,杨进,等.疏风解毒胶囊对慢性阻塞性肺疾病急性加重期的疗效评价[J].中华中医药杂志,2017,17(1):347-350.
[8]杜晓秋,周军,张秋娣.不同评价指标在慢性阻塞性肺疾病患者综合评估中的应用[J].中国全科医学,2016,11(5):511-516.
[9]王靓雅,刘冰,祖权,等.补肺健脾益肾方治疗稳定期慢性阻塞性肺疾病营养状况和对免疫功能的影响[J].中国实验方剂学杂志,2017,27(22):182-187.
[10]洪敏俐,杨朝阳,柯庚申,等.愈肺宁方对慢性阻塞性肺疾病稳定期患者中医证素的影响[J].中华中医药杂志,2015,9(5):1666-1669.
[11]潘宜,黄晓颖.布地奈德联合沙丁胺醇和异丙托溴铵治疗慢性阻塞性肺疾病急性发作期的临床研究[J].中国临床药理学杂志,2016,32(15):1347-1349.
[12]陈四清,谢文英,尚立芝,等.二陈汤加味对慢性阻塞性肺疾病急性加重期老年患者免疫功能及CCL18,CC16,IL-8和s ICAM-1的影响[J].中国实验方剂学杂志,2017,27(10):171-177.
[13]兰智慧,钟凌云,陈章生,等.补益宗气法对慢性阻塞性肺疾病大鼠气道重塑的影响[J].中华中医药学刊,2015,10(11):2659-2661.
[14]李建生,张海龙,王海峰,等.慢性阻塞性肺疾病证候演变特点临床调查[J].中医杂志,2017,58(9):772-776.
[15]郭贵州,宋文龙,甘桃梅,等.基于MMP-9/TIMP-1失衡研究补益宗气方干预慢性阻塞性肺疾病大鼠气道重塑的机制[J].中华中医药杂志,2016,16(11):4678-4680.
[16]王丽华,张元兵,兰智慧,等.国医大师洪广祥教授治疗慢性阻塞性肺疾病经验[J].中华中医药杂志,2016,10(7):2590-2592.
[17]郁东伟,束永前.中医综合疗法治疗慢性阻塞性肺疾病(COPD)稳定期营养状况及肺功能的改善评价[J].中华中医药学刊,2015,6(11):2608-2610.
[18]娄明远.中西医结合治疗不同严重度稳定期慢性阻塞性肺疾病的影响[J].中华中医药学刊,2017,35(9):2453-2455.
[19]张鹏飞,梁炜,谭玉萍,等.银杏叶提取物对慢性阻塞性肺疾病大鼠肺组织MMP-1及MMP-9表达的影响[J].辽宁中医杂志,2017,31(4):849-851.
[20]尤辉,王梅芳,刘玉全,等.乌司他丁对COPD合并呼吸衰竭患者血清COX-2,PGE2及PLA2的影响[J].现代生物医学进展,2015,15(35):6889-6891.
[21]何主强,殷莉,黄姗姗.环氧化酶-2及细胞因子在创伤后应激障碍患者中的表达变化及意义[J].实用医学杂志,2015,16(19):3166-3168.
[22]赵年昆,李岩.苏黄止咳胶囊治疗慢性阻塞性肺疾病急性发作期的临床疗效及长期随访观察[J].辽宁中医杂志,2017,19(6):1235-1238.